RADIANCE BIOPHARMA - Key Persons
Job Titles:
- Chief Scientific Officer
- Member of the Management Team
A. Graham Pockley serves as Chief Science Officer (CSO) of Radiance. He also serves as CSO of Alphageneron Pharmaceuticals, and ExoCellulular Diagnostics and CEO of multimmune GmbH, Munich, a clinical stage company developing NK cell therapy focused on membrane Hsp70. He is an Emeritus Professor of Immunobiology and former Director of the John van Geest Cancer Research Centre at Nottingham Trent University, UK. Between 2010 and 2021 he was the Founder and Chairman of Chromocyte, an online resource for flow cytometry and other antibody-related techniques, prior to its acquisition by Biocompare. Graham's extensive academic career has focused on the immunobiology of disease, the development of new immunotherapeutic strategies for treating aggressive and ‘orphan' cancers, new approaches for analysing and interpreting complex datasets and defining new biomarkers of disease presence,
Graham holds a BSc (Hons) in Biochemistry from the University of Sheffield, UK and a PhD in Immunology from Sheffield Hallam University, also in Sheffield, UK.
Job Titles:
- Chief Medical Officer
- Member of the Management Team
- Interim Chief Medical Officer
Dr. Forrest serves as Chief Medical Officer of Radiance. For over 30 years, Dr. Forrest worked as a pharmaceutical industry physician leading the global development of pharmaceuticals, vaccines, and biological drugs. As Senior Vice President at Wyeth Vaccines, Dr. Forrest was responsible for all late phase clinical and pharmaceutical science development activities for vaccines in the Wyeth pipeline, including Prevnar 13®; the meningococcal B vaccine (Trumemba®) and an early investigational Staphylococcus aureus vaccine. He led the clinical activities supporting the market authorization for RotaShield® (EU), Prevnar® (Global), and FluMist®. He served as Board Member, and Executive Director of R&D for Wyeth Labs (acquired by Pfizer), and Sr. VP at Pfizer. He oversaw the marketing approval of the first ever Antibody Drug Conjugate Gemtuzumab ozogamicin (brand name Mylotarg) in Japan. Mylotarg received accelerated approval by the FDA in 2000 and was the first antibody drug conjugate to be approved. At Chiron Corporation he was the global clinical team leader for a meningococcal C conjugate vaccine (Menjugate®). Dr. Forrest is an investment banker with a Westchester, NY based investment bank (Young America Capital, LLC) where he co-heads Life Sciences Investment Banking. He also owns an independent FINRA-registered investment advisory firm that is regulated by the State of New York (Aeolian Advisors Corp.).
Marc E. Lippman, is a professor in the departments of oncology and medicine at Georgetown University Medical Center. He formerly served as deputy director of Sylvester Comprehensive Cancer Center at the University of Miami, as well as the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Miller School of Medicine. He also served as Head of the Medical Breast Cancer Section of the National Cancer Institute. Throughout his career, Lippman has garnered many honors including a Clinical Investigator Award from the American Federation for Clinical Research, the Transatlantic Medal and Lecture from the British Endocrine Societies, the Astwood Award from the Endocrine Society, the Bernard Fisher Award from the University of Pittsburgh, the Rosenthal Award from the American Association for Cancer Research, and the Brinker Award for Basic Science from the Komen Foundation. Dr. Lippman has published over 500 peer-reviewed articles and is editor-in-chief of Breast Cancer Research and Treatment.
Gabriele Multhoff currently holds a C3 Professorship in Experimental Radiation Oncology/Radiation Biology at the Department of Radiation Oncology and Radiation Therapy at the Klinikum rechts der Isar, Technical University of Munich (TUM). She is also the Founder and CSO of Multimmune GmbH and is the named inventor on multiple granted patents relating to theranostics based on her discovery of membrane Hsp70 expression on tumor cells.
Prof. Gabriele Multhoff's research is the development of innovative immunotherapies based on targeting membrane Hsp70 on cancers. Her research led to a randomized, multicenter clinical phase II study for patients with Advanced Stage IIIb non-small cell lung carcinoma (NSCLC) after radiochemotherapy funded by the German Federal Ministry of Education and Research (BMBF) which confirmed the therapeutic potential of such targeted therapeutics.
She also invented a novel ELISA cancer monitoring test (US patent granted) which quantifies levels of exosomal, tumor-derived Hsp70 in the blood of patients.
Job Titles:
- CEO
- Founder
- Member of the Management Team
Robert Brooks, JD is the Founder and serves as Chief Executive Officer (CEO) of Radiance. Robert brings over 30 years of experience in the biotechnology, financial and legal industries. In 2022, he founded and serves as Chairman and CEO of Exocellular Diagnostics, a commercial stage company developing cancer diagnostics, with marketing approval in the European Union. In 2020, he founded and serves as Chairman and CEO of Alphageneron Pharmaceuticals, a clinical stage company focused on natural killer (NK) cell therapy. From 2016, he has been Managing Director of US Global Partners, LLC, investment firm. In 2015, he founded and serve as Chairman and CEO of Aurora Biopharma, a biotechnology company developing CAR T cell therapy for solid tumors. In 2012, he founded and served as Chairman and CEO of Medvax Technologies, a clinical stage biotechnology company focused on developing cancer vaccines. From 2000 to 2010, Mr. Brooks practiced corporate-securities law. From 1987 until 1999, he was employed in the financial and investment banking industry. He holds a Juris Doctorate (JD) degree from the University of Miami, Florida, and an undergraduate Bachelor of Science degree, Cum Laude, in Biology/Pre-Medicine.
He has held a Securities license. He serves on the Board of Directors of Medtherapy, Inc., a global cell and gene manufacturer.